NuCana plc
NUC-7738
melanoma
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews NUC-7738 for melanoma around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 6-K
verified 12h ago
“We also anticipate seeking regulatory guidance from the U.S. Food and Drug Administration (FDA) in 2026 regarding the potential registrational pathway for NUC-7738 in melanoma.”